Organogenesis Acquires Shire’s Dermagraft Amid Reimbursement Challenges
This article was originally published in The Gray Sheet
Dublin-based Shire’s decision to sell Dermagraft and its assets to its competitor was made in light of substantial Medicare pay cuts that took effect this year based on policies in CMS’ 2014 hospital outpatient prospective payment system regulation.
You may also be interested in...
The $350m settlement resolves False Claims Act allegations Shire and its subsidiaries used tactics including lavish meals, free medical equipment, unearned speaker payments and cash to encourage doctors to prescribe the company’s Dermagraft human skin substitute.
Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.
The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.